Аңдатпа
Mutations of isocitrate dehydrogenase 1, observed in 7-14% of patients with acute myeloid leukemia, have been associated with unfavorable prognosis. Ivosidenib (AG-120) is an oral, reversible small-molecule inhibitor of mutated IDH1 enzyme. This review provides a brief summary of ivosidenib monotherapy for patients with relapsed or refractory acute myeloid leukemia.